Maze Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MAZE and other ETFs, options, and stocks.

About MAZE

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. 

CEO
Jason V. Coloma
CEOJason V. Coloma
Employees
125
Employees125
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
2017
Founded2017
Employees
125
Employees125

MAZE Key Statistics

Market cap
1.53B
Market cap1.53B
Price-Earnings ratio
-14.07
Price-Earnings ratio-14.07
Dividend yield
Dividend yield
Average volume
1.54M
Average volume1.54M
High today
$60.00
High today$60.00
Low today
$29.77
Low today$29.77
Open price
$39.99
Open price$39.99
Volume
8.23M
Volume8.23M
52 Week high
$60.00
52 Week high$60.00
52 Week low
$6.71
52 Week low$6.71

Stock Snapshot

The current Maze Therapeutics(MAZE) stock price is $31.90, with a market capitalization of 1.53B. The stock trades at a price-to-earnings (P/E) ratio of -14.07.

On 2026-03-25, Maze Therapeutics(MAZE) stock traded between a low of $29.77 and a high of $60.00. Shares are currently priced at $31.90, which is +7.2% above the low and -46.8% below the high.

The Maze Therapeutics(MAZE)'s current trading volume is 8.23M, compared to an average daily volume of 1.54M.

During the past year, Maze Therapeutics(MAZE) stock moved between $6.71 at its lowest and $60.00 at its peak.

During the past year, Maze Therapeutics(MAZE) stock moved between $6.71 at its lowest and $60.00 at its peak.

MAZE News

Benzinga 11h
Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829

• Maze Therapeutics stock is among today’s weakest performers. What’s behind MAZE decline? AMKD is a type of kidney disease caused by variants (changes) in the...

Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829
TipRanks 16h
Maze Therapeutics adds Neil Kumar to board leadership

Maze Therapeutics, Inc. ( (MAZE) ) has shared an update. Maze Therapeutics reported fourth-quarter and full-year 2025 results on March 25, 2026, alongside posi...

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own MAZE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.